Nanoparticles and targeted drug delivery in cancer therapy

Immunology Letters

Volumn 190, Issue , 2017, Pages 64-83

  Bahrami, Behdokht ^a,b   Hojjat Farsangi, Mohammad ^c,d   Mohammadi, Hamed ^e,f   Anvari, Enayat ^g   Ghalamfarsa, Ghasem ^h   Yousefi, Mehdi ^e,f   Jadidi Niaragh, Farhad ^e,f,i  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h YASUJ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer immunotherapy; Nanoparticles; Targeted drug delivery

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; APTAMER; CARBOHYDRATE; CELL PENETRATING PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; INTEGRIN; LECTIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOCARRIER; PEPTIDE; TRANSFERRIN RECEPTOR; VITAMIN; NANOPARTICLE;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; ADVERSE DRUG REACTION; ANIMAL; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 85026733889     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2017.07.015     Document Type: Review

References (330)

1. Farokhzad, O.C., Langer, R., Impact of nanotechnology on drug delivery. ACS Nano 3:1 (2009), 16–20.
2. Petros, R.A., DeSimone, J.M., Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9:8 (2010), 615–627.
3. Zhang, J., Sun, H., Ma, P.X., Host- guest interaction mediated polymeric assemblies: multifunctional nanoparticles for drug and gene delivery. ACS Nano 4:2 (2010), 1049–1059.
4. Bombelli, F.B., Webster, C.A., Moncrieff, M., Sherwood, V., The scope of nanoparticle therapies for future metastatic melanoma treatment. Lancet Oncol. 15:1 (2014), e22–e32.
5. Qi, H., Li, Z., Du, K., Mu, K., Zhou, Q., Liang, S., et al. Transferrin-targeted magnetic/fluorescence micelles as a specific bi-functional nanoprobe for imaging liver tumor. Nanoscale Res. Lett. 9:1 (2014), 1–9.
6. Nanoparticles for Drug Delivery in Cancer Treatment. Urologic Oncology: Seminars and Original Investigations. Haley, B., Frenkel, E., (eds.), 2008, Elsevier.
7. Jadidi-Niaragh, F., Atyabi, F., Rastegari, A., Kheshtchin, N., Arab, S., Hassannia, H., et al. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. J. Control. Release 246 (2017), 46–59.
8. Choi, H.S., Liu, W., Misra, P., Tanaka, E., Zimmer, J.P., Ipe, B.I., et al. Renal clearance of quantum dots. Nat. Biotechnol. 25:10 (2007), 1165–1170.
9. Najafi-Hajivar, S., Zakeri-Milani, P., Mohammadi, H., Niazi, M., Soleymani-Goloujeh, M., Baradaran, B., et al. Overview on experimental models of interactions between nanoparticles and the immune system. Biomed. Pharmacother. 83 (2016), 1365–1378.
10. Davis, M.E., Shin, D.M., Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7:9 (2008), 771–782.
11. Decuzzi, P., Pasqualini, R., Arap, W., Ferrari, M., Intravascular delivery of particulate systems: does geometry really matter?. Pharm. Res. 26:1 (2009), 235–243.
12. Perrault, S.D., Walkey, C., Jennings, T., Fischer, H.C., Chan, W.C., Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9:5 (2009), 1909–1915.
13. Kim, C., Cho, E.C., Chen, J., Song, K.H., Au, L., Favazza, C., et al. In vivo molecular photoacoustic tomography of melanomas targeted by bioconjugated gold nanocages. ACS Nano 4:8 (2010), 4559–4564.
14. Hawker, C.J., Wooley, K.L., The convergence of synthetic organic and polymer chemistries. Science 309:5738 (2005), 1200–1205.
15. Johnson, S., Bangham, A., Potassium permeability of single compartment liposomes with and without valinomycin. Biochim. et Biophys. Acta (BBA): Biomembr. 193:1 (1969), 82–91.
16. Malam, Y., Loizidou, M., Seifalian, A.M., Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30:11 (2009), 592–599.
17. Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4:2 (2005), 145–160.
18. Hu, C.-M.J., Kaushal, S., Cao, H.S.T., Aryal, S., Sartor, M., Esener, S., et al. Half-antibody functionalized lipid- polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol. Pharm. 7:3 (2010), 914–920.
19. Misra, R., Acharya, S., Sahoo, S.K., Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov. Today 15:19 (2010), 842–850.
20. Doktorovova, S., Souto, E.B., Silva, A.M., Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers–a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 87:1 (2014), 1–18.
21. Selvamuthukumar, S., Velmurugan, R., Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis., 11, 2012, 159.
22. Shao, Z., Shao, J., Tan, B., Guan, S., Liu, Z., Zhao, Z., et al. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int. J. Nanomed., 10, 2015, 1223.
23. Müller, R., Mehnert, W., Lucks, J.-S., Schwarz, C., Zur Mühlen, A., Meyhers, H., et al. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41:1 (1995), 62–69.
24. Wong, H.L., Bendayan, R., Rauth, A.M., Li, Y., Wu, X.Y., Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59:6 (2007), 491–504.
25. Acharya, S., Sahoo, S.K., PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 63:3 (2011), 170–183.
26. Astruc, D., Boisselier, E., Ornelas, C.t., Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem. Rev. 110:4 (2010), 1857–1959.
27. Tomalia, D., Uppuluri, S., Swanson, D., Brothers, H., Piehler, L., Li, J., et al. Dendritic Macromolecules: A Fourth Major Class of Polymer Architecture–New Properties Driven by Architecture. MRS Proceedings. 1998, Cambridge Univ Press.
28. Hawker, C.J., Frechet, J.M., Preparation of polymers with controlled molecular architecture: a new convergent approach to dendritic macromolecules. J. Am. Chem. Soc. 112:21 (1990), 7638–7647.
29. Svenson, S., Tomalia, D.A., Dendrimers in biomedical applications—reflections on the field. Adv. Drug Deliv. Rev. 57:15 (2005), 2106–2129.
30. Turrin, C.O., Caminade, A.M., Dendrimers for imaging. dendrimers: towards catalytic. Mater. Biomed. Uses, 2011, 393–412.
31. Menjoge, A.R., Kannan, R.M., Tomalia, D.A., Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 15:5 (2010), 171–185.
32. Peng, X.-H., Qian, X., Mao, H., Wang, A.Y., Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int. J. Nanomed., 3(3), 2008, 311.
33. Yu, M.K., Jeong, Y.Y., Park, J., Park, S., Kim, J.W., Min, J.J., et al. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew. Chem. Int. Ed. 47:29 (2008), 5362–5365.
34. Sun, C., Du, K., Fang, C., Bhattarai, N., Veiseh, O., Kievit, F., et al. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano 4:4 (2010), 2402–2410.
35. Kievit, F.M., Zhang, M., Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res. 44:10 (2011), 853–862.
36. Eigler, D.M., Schweizer, E.K., Positioning single atoms with a scanning tunnelling microscope. Nature 344:6266 (1990), 524–526.
37. Park, J.H., von Maltzahn, G., Ruoslahti, E., Bhatia, S.N., Sailor, M.J., Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew. Chem. 120:38 (2008), 7394–7398.
38. Libutti, S., Paciotti, G., Myer, L., Haynes, R., Gannon, W., Walker, M., et al. Results of a Completed Phase I Clinical Trial of CYT-6091: A Pegylated Colloidal Gold-TNF Nanomedicine. ASCO Annual Meeting Proceedings. 2009.
39. Blasiak, B., van Veggel, F.C., Tomanek, B., Applications of nanoparticles for MRI cancer diagnosis and therapy. J. Nanomater., 2013, 2013, 12.
40. Yameen, B., Choi, W.I., Vilos, C., Swami, A., Shi, J., Farokhzad, O.C., Insight into nanoparticle cellular uptake and intracellular targeting. J. Control. Release 190 (2014), 485–499.
41. Xiang, S., Tong, H., Shi, Q., Fernandes, J.C., Jin, T., Dai, K., et al. Uptake mechanisms of non-viral gene delivery. J. Control. Release 158:3 (2012), 371–378.
42. Zappavigna, S., Misso, G., Falanga, A., Perillo, E., Novellino, E., Galdiero, M., et al. Nanocarriers conjugated with cell penetrating peptides: new trojan horses by modern ulysses. Curr. Pharm. Biotechnol. 17:8 (2016), 700–722.
43. Sahay, G., Alakhova, D.Y., Kabanov, A.V., Endocytosis of nanomedicines. J. Control. Release 145:3 (2010), 182–195.
44. Rappoport, J.Z., Focusing on clathrin-mediated endocytosis. Biochem. J 412:3 (2008), 415–423.
45. Pucadyil, T.J., Schmid, S.L., Conserved functions of membrane active GTPases in coated vesicle formation. Science 325:5945 (2009), 1217–1220.
46. Vogel, U., Sandvig, K., van Deurs, B., Expression of caveolin-1 and polarized formation of invaginated caveolae in Caco-2 and MDCK II cells. J. Cell Sci. 111:6 (1998), 825–832.
47. Qaddoumi, M.G., Ueda, H., Yang, J., Davda, J., Labhasetwar, V., Lee, V.H., The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm. Res. 21:4 (2004), 641–648.
48. Nan, A., Bai, X., Son, S.J., Lee, S.B., Ghandehari, H., Cellular uptake and cytotoxicity of silica nanotubes. Nano Lett. 8:8 (2008), 2150–2154.
49. Ma, Z., Lim, L.-Y., Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 20:11 (2003), 1812–1819.
50. Tekle, C., Deurs Bv Sandvig, K., Iversen, T.G., Cellular trafficking of quantum dot-ligand bioconjugates and their induction of changes in normal routing of unconjugated ligands. Nano Lett. 8:7 (2008), 1858–1865.
51. Medina-Kauwe, L.K., Alternative endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery?. Adv. Drug Deliv. Rev. 59:8 (2007), 798–809.
52. Parton, R.G., Simons, K., The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8:3 (2007), 185–194.
53. Perumal, O.P., Inapagolla, R., Kannan, S., Kannan, R.M., The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials 29:24 (2008), 3469–3476.
54. Benmerah, A., Lamaze, C., Clathrin‐Coated Pits: Vive La Différence?. Traffic 8:8 (2007), 970–982.
55. Haigler, H.T., McKANNA, J.A., Cohen, S., Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. J. Cell Biol. 83:1 (1979), 82–90.
56. Kou, L., Sun, J., Zhai, Y., He, Z., The endocytosis and intracellular fate of nanomedicines: implication for rational design. Asian J. Pharm. Sci. 8:1 (2013), 1–10.
57. Mayor, S., Pagano, R.E., Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 8:8 (2007), 603–612.
58. Mercer, J., Helenius, A., Virus entry by macropinocytosis. Nat. Cell Biol. 11:5 (2009), 510–520.
59. Nam, H.Y., Kwon, S.M., Chung, H., Lee, S.-Y., Kwon, S.-H., Jeon, H., et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 135:3 (2009), 259–267.
60. Bertrand, N., Leroux, J.-C., The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Release 161:2 (2012), 152–163.
61. Prabhu, R.H., Patravale, V.B., Joshi, M.D., Polymeric nanoparticles for targeted treatment in oncology: current insights. Int. J. Nanomed., 10, 2015, 1001.
62. Sinha, R., Kim, G.J., Nie, S., Shin, D.M., Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5:8 (2006), 1909–1917.
63. Smith, A.M., Duan, H., Mohs, A.M., Nie, S., Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60:11 (2008), 1226–1240.
64. Ferreira, D.d.S., Lopes, S.C.d.A., Franco, M.S., Oliveira, M.C., pH-sensitive liposomes for drug delivery in cancer treatment. Therap. Deliv. 4:9 (2013), 1099–1123.
65. Bae, Y.H., Park, K., Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release, 153(3), 2011, 198.
66. Danhier, F., Feron, O., Préat, V., To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148:2 (2010), 135–146.
67. Choi, C.H.J., Alabi, C.A., Webster, P., Davis, M.E., Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. 107:3 (2010), 1235–1240.
68. Georgieva, J.V., Hoekstra, D., Zuhorn, I.S., Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood–brain barrier. Pharmaceutics 6:4 (2014), 557–583.
69. Li, L., Fang, C.J., Ryan, J.C., Niemi, E.C., Lebrón, J.A., Björkman, P.J., et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc. Natl. Acad. Sci. 107:8 (2010), 3505–3510.
70. Trinder, D., Baker, E., Transferrin receptor 2: a new molecule in iron metabolism. Int. J. Biochem. Cell Biol. 35:3 (2003), 292–296.
71. Gray, B.P., Li, S., Brown, K.C., From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjugate Chem. 24:1 (2013), 85–96.
72. Daniels, T.R., Bernabeu, E., Rodríguez, J.A., Patel, S., Kozman, M., Chiappetta, D.A., et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. et Biophys. Acta (BBA): Gen. Subj. 1820:3 (2012), 291–317.
73. Qian, Z.M., Li, H., Sun, H., Ho, K., Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54:4 (2002), 561–587.
74. Zhao, C., Liu, X., Liu, J., Yang, Z., Rong, X., Li, M., et al. Transferrin conjugated poly (γ-glutamic acid-maleimide-co-l-lactide)-1, 2-dipalmitoylsn-glycero-3-phosphoethanolamine copolymer nanoparticles for targeting drug delivery. Colloids Surf. B: Biointerfaces 123 (2014), 787–796.
75. Ren, W.-H., Chang, J., Yan, C.-H., Qian, X.-M., Long, L.-X., He, B., et al. Development of transferrin functionalized poly (ethylene glycol)/poly (lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma. J. Mater. Sci. 21:9 (2010), 2673–2681.
76. Ding, W., Guo, L., Immobilized transferrin Fe3O4@ SiO2 nanoparticle with high doxorubicin loading for dual-targeted tumor drug delivery. Int. J. Nanomed., 8, 2013, 4631.
77. Malarvizhi, G.L., Retnakumari, A.P., Nair, S., Koyakutty, M., Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomed.: Nanotechnol. Biol. Med. 10:8 (2014), 1649–1659.
78. Guo, Y., Wang, L., Lv, P., Zhang, P., Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol. Lett. 9:3 (2015), 1065–1072.
79. Bao, W., Liu, R., Wang, Y., Wang, F., Xia, G., Zhang, H., et al. Plga-Pll-Peg-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int. J. Nanomed., 10, 2015, 557.
80. Koppu, S., Oh, Y.J., Edrada-Ebel, R., Blatchford, D.R., Tetley, L., Tate, R.J., et al. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J. Control. Release 143:2 (2010), 215–221.
81. Han, L., Huang, R., Liu, S., Huang, S., Jiang, C., Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol. Pharm. 7:6 (2010), 2156–2165.
82. Ghalamfarsa, G., Hojjat-Farsangi, M., Mohammadnia-Afrouzi, M., Anvari, E., Farhadi, S., Yousefi, M., et al. Application of nanomedicine for crossing the blood–brain barrier: theranostic opportunities in multiple sclerosis. J. Immunotoxicol. 13:5 (2016), 603–619.
83. Jiang, W., Xie, H., Ghoorah, D., Shang, Y., Shi, H., Liu, F., et al. Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model. PLoS One, 7(5), 2012, e37376.
84. Porru, M., Zappavigna, S., Salzano, G., Luce, A., Stoppacciaro, A., Balestrieri, M.L., et al. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget, 5(21), 2014, 10446.
85. Kopecka, J., Porto, S., Lusa, S., Gazzano, E., Salzano, G., Pinzòn-Daza, M.L., et al. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget, 7(15), 2016, 20753.
86. Salzano, G., Marra, M., Porru, M., Zappavigna, S., Abbruzzese, A., La Rotonda, M., et al. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int. J. Pharm. 403:1 (2011), 292–297.
87. Agrati, C., Marianecci, C., Sennato, S., Carafa, M., Bordoni, V., Cimini, E., et al. Multicompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid delivery. Nanomed. Nanotechnol. Biol. Med. 7:2 (2011), 153–161.
88. Kopecka, J., Porto, S., Lusa, S., Gazzano, E., Salzano, G., Giordano, A., et al. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget, 6(31), 2015, 31461.
89. Marra, M., Salzano, G., Leonetti, C., Porru, M., Franco, R., Zappavigna, S., et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol. Adv. 30:1 (2012), 302–309.
90. Dixit, S., Novak, T., Miller, K., Zhu, Y., Kenney, M.E., Broome, A.-M., Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale 7:5 (2015), 1782–1790.
91. Ulbrich, K., Hekmatara, T., Herbert, E., Kreuter, J., Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood?brain barrier (BBB). Eur. J. Pharm. Biopharm. 71:2 (2009), 251–256.
92. Korkusuz, H., Ulbrich, K., Welzel, K., Koeberle, V., Watcharin, W., Bahr, U., et al. Transferrin-coated gadolinium nanoparticles as MRI contrast agent. Mol. Imaging Biol. 15:2 (2013), 148–154.
93. Eavarone, D.A., Yu, X., Bellamkonda, R.V., Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J. Biomed. Mater. Res. 51:1 (2000), 10–14.
94. Gupta, Y., Jain, A., Jain, S.K., Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 59:7 (2007), 935–940.
95. Xu, L., Frederik, P., Pirollo, K.F., Tang, W.-H., Rait, A., Xiang, L.-M., et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum. Gene Ther. 13:3 (2002), 469–481.
96. Zhang, X., Koh, C.G., Yu, B., Liu, S., Piao, L., Marcucci, G., et al. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model. Pharm. Res. 26:6 (2009), 1516–1524.
97. Chiu, R.Y., Tsuji, T., Wang, S.J., Wang, J., Liu, C.T., Kamei, D.T., Improving the systemic drug delivery efficacy of nanoparticles using a transferrin variant for targeting. J. Control. Release 180 (2014), 33–41.
98. Yoon, D.J., Chu, D.S., Ng, C.W., Pham, E.A., Mason, A.B., Hudson, D.M., et al. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J. Control. Release 133:3 (2009), 178–184.
99. Yoon, D.J., Kwan, B.H., Chao, F.C., Nicolaides, T.P., Phillips, J.J., Lam, G.Y., et al. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res. 70:11 (2010), 4520–4527.
100. Hu, K., Li, J., Shen, Y., Lu, W., Gao, X., Zhang, Q., et al. Lactoferrin-conjugated PEG–PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Control. Release 134:1 (2009), 55–61.
101. Davis, M.E., The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6:3 (2009), 659–668.
102. Elliott, G., O'Hare, P., Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:2 (1997), 223–233.
103. Frankel, A.D., Pabo, C.O., Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:6 (1988), 1189–1193.
104. Koren, E., Torchilin, V.P., Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 18:7 (2012), 385–393.
105. Milletti, F., Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 17:15 (2012), 850–860.
106. Madani, F., Lindberg, S., Langel, Ü., Futaki, S., Gräslund, A., Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys., 2011, 2011.
107. Vasconcelos, A., Vega, E., Pérez, Y., Gómara, M.J., García, M.L., Haro, I., Conjugation of cell-penetrating peptides with poly (lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery. Int. J. Nanomed., 10, 2015, 609.
108. Derossi, D., Joliot, A.H., Chassaing, G., Prochiantz, A., The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269:14 (1994), 10444–10450.
109. Torchilin, V.P., Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60:4 (2008), 548–558.
110. Josephson, L., Tung, C.-H., Moore, A., Weissleder, R., High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjugate Chem. 10:2 (1999), 186–191.
111. Heitz, F., Morris, M.C., Divita, G., Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157:2 (2009), 195–206.
112. Kaufman, C.L., Williams, M., Ryle, L.M., Smith, T.L., Tanner, M., Ho, C., Superparamagnetic iron oxide particles transactivator protein-fluorescein isothiocyanate particle labeling for in vivo magnetic resonance imaging detection of cell migration: uptake and durability. Transplantation 76:7 (2003), 1043–1046.
113. Harris, T.J., von Maltzahn, G., Lord, M.E., Park, J.H., Agrawal, A., Min, D.H., et al. Protease-triggered unveiling of bioactive nanoparticles. Small 4:9 (2008), 1307–1312.
114. Wen, X., Wang, K., Zhao, Z., Zhang, Y., Sun, T., Zhang, F., et al. Brain-Targeted Delivery of Trans-Activating Transcriptor-Conjugated Magnetic PLGA/Lipid Nanoparticles. 2014.
115. Asai, T., Tsuzuku, T., Takahashi, S., Okamoto, A., Dewa, T., Nango, M., et al. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. Biochem. Biophys. Res. Commun. 444:4 (2014), 599–604.
116. Torchilin, V.P., Levchenko, T.S., Rammohan, R., Volodina, N., Papahadjopoulos-Sternberg, B., D'Souza, G.G., Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes. Proc. Natl. Acad. Sci. 100:4 (2003), 1972–1977.
117. Pappalardo, J.S., Langellotti, C.A., Di Giacomo, S., Olivera, V., Quattrocchi, V., Zamorano, P.I., et al. In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes. Int. J. Nanomed., 9, 2014, 963.
118. Fu, H., Shi, K., Hu, G., Yang, Y., Kuang, Q., Lu, L., et al. Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly (Ethylene glycol). J. Pharm. Sci. 104:3 (2015), 1160–1173.
119. Jiang, T., Zhang, Z., Zhang, Y., Lv, H., Zhou, J., Li, C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 33:36 (2012), 9246–9258.
120. Balzeau, J., Pinier, M., Berges, R., Saulnier, P., Benoit, J.-P., Eyer, J., The effect of functionalizing lipid nanocapsules with NFL-TBS: 40–63 peptide on their uptake by glioblastoma cells. Biomaterials 34:13 (2013), 3381–3389.
121. Yang, Y., Xie, X., Yang, Y., Zhang, H., Mei, X., Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy. J. Pharm. Sci. 104:4 (2015), 1328–1329.
122. Cryan, S.-A., Devocelle, M., Moran, P.J., Hickey, A.J., Kelly, J.G., Increased intracellular targeting to airway cells using octaarginine-coated liposomes: in vitro assessment of their suitability for inhalation. Mol. Pharm. 3:2 (2006), 104–112.
123. Patlolla, R.R., Desai, P.R., Belay, K., Singh, M.S., Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials 31:21 (2010), 5598–5607.
124. Sethuraman, V.A., Lee, M.C., Bae, Y.H., A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm. Res. 25:3 (2008), 657–666.
125. Torchilin, V.P., Rammohan, R., Weissig, V., Levchenko, T.S., TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. 98:15 (2001), 8786–8791.
126. Rudolph, C., Rosenecker, J., Formation of solid lipid nanoparticle (SLN)–gene vector complexes for transfection of mammalian cells in vitro. Cold Spring Harb. Protoc., 2012(3), 2012 (pdb.prot068122).
127. Liu, Y., Mei, L., Yu, Q., Xu, C., Qiu, Y., Yang, Y., et al. Multifunctional tandem peptide modified paclitaxel loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma. ACS Appl. Mater. Interfaces, 2015.
128. Yuan, M., Qiu, Y., Zhang, L., Gao, H., He, Q., Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma. Drug Deliv., 2015, 1–13 (ahead-of-print).
129. Zheng, C., Ma, C., Bai, E., Yang, K., Xu, R., Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma. Int. J. Clin. Exp. Med., 8(2), 2015, 1658.
130. Liu, B.R., Li, J.-F., Lu, S.-W., Lee, H.-J., Huang, Y.-W., Shannon, K.B., et al. Cellular internalization of quantum dots noncovalently conjugated with arginine-rich cell-penetrating peptides. J. Nanosci. Nanotechnol., 10(10), 2010, 6534.
131. Liu, B.R., Winiarz, J.G., Moon, J.-S., Lo, S.-Y., Huang, Y.-W., Aronstam, R.S., et al. Synthesis, characterization and applications of carboxylated and polyethylene-glycolated bifunctionalized InP/ZnS quantum dots in cellular internalization mediated by cell-penetrating peptides. Colloids Surf. B: Biointerfaces 111 (2013), 162–170.
132. Stroh, M., Zimmer, J.P., Duda, D.G., Levchenko, T.S., Cohen, K.S., Brown, E.B., et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 11:6 (2005), 678–682.
133. Li, J., Liu, F., Shao, Q., Min, Y., Costa, M., Yeow, E.K., et al. Enzyme-responsive cell-penetrating peptide conjugated mesoporous silica quantum dot nanocarriers for controlled release of nucleus-targeted drug molecules and real-time intracellular fluorescence imaging of tumor cells. Adv. Healthcare Mater. 3:8 (2014), 1230–1239.
134. Park, H., Tsutsumi, H., Mihara, H., Cell-selective intracellular drug delivery using doxorubicin and α-helical peptides conjugated to gold nanoparticles. Biomaterials 35:10 (2014), 3480–3487.
135. Dekiwadia, C.D., Lawrie, A.C., Fecondo, J.V., Peptide-mediated cell penetration and targeted delivery of gold nanoparticles into lysosomes. J. Pept. Sci. 18:8 (2012), 527–534.
136. de la Fuente, J.M., Berry, C.C., Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjugate Chem. 16:5 (2005), 1176–1180.
137. Yuan, H., Fales, A.M., Vo-Dinh, T., TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance. J. Am. Chem. Soc. 134:28 (2012), 11358–11361.
138. Winer, I., Wang, S., Lee, Y.-E.K., Fan, W., Gong, Y., Burgos-Ojeda, D., et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 70:21 (2010), 8674–8683.
139. Lee, J.Y., Choi, Y.S., Suh, J.S., Kwon, Y.M., Yang, V.C., Lee, S.J., et al. Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int. J. Cancer 128:10 (2011), 2470–2480.
140. Malhotra, M., Tomaro-Duchesneau, C., Prakash, S., Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 34:4 (2013), 1270–1280.
141. Egusquiaguirre, S.P., Manguán-García, C., Pintado-Berninches, L., Iarriccio, L., Carbajo, D., Albericio, F., et al. Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24: 2 peptide to cells: a promising approach for the treatment of defective telomerase disorders. Eur. J. Pharm. Biopharm. 91 (2015), 91–102.
142. Siahmansouri, H., Somi, M.H., Babaloo, Z., Baradaran, B., Jadidi-Niaragh, F., Atyabi, F., et al. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. J. Pharm. Pharmacol. 68:9 (2016), 1119–1130.
143. Qin, Y., Chen, H., Yuan, W., Kuai, R., Zhang, Q., Xie, F., et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int. J. Pharm. 419:1 (2011), 85–95.
144. Cheng, Y., Dai, Q., Morshed, R.A., Fan, X., Wegscheid, M.L., Wainwright, D.A., et al. Blood-Brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small 10:24 (2014), 5137–5150.
145. Lee, C.-Y., Li, J.-F., Liou, J.-S., Charng, Y.-C., Huang, Y.-W., Lee, H.-J., A gene delivery system for human cells mediated by both a cell-penetrating peptide and a piggyBac transposase. Biomaterials 32:26 (2011), 6264–6276.
146. Shin, M.C., Zhang, J., Min, K.A., Lee, K., Byun, Y., David, A.E., et al. Cell-penetrating peptides: achievements and challenges in application for cancer treatment. J. Biomed. Mater. Res. A 102:2 (2014), 575–587.
147. Meade, B.R., Dowdy, S.F., Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59:2 (2007), 134–140.
148. Park, Y.J., Chang, L.-C., Liang, J.F., Moon, C., Chung, C.-P., Yang, V.C., Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J. 19:11 (2005), 1555–1557.
149. Järver, P., Mäger, I., Langel, Ü., In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol. Sci. 31:11 (2010), 528–535.
150. Rousselle, C., Smirnova, M., Clair, P., Lefauconnier, J.-M., Chavanieu, A., Calas, B., et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 296:1 (2001), 124–131.
151. Prassl, R., Laggner, P., Molecular structure of low density lipoprotein: current status and future challenges. Eur. Biophys. J. 38:2 (2009), 145–158.
152. Firestone, R.A., Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem. 5:2 (1994), 105–113.
153. Zheng, G., Chen, J., Li, H., Glickson, J.D., Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl. Acad. Sci. U. S. A. 102:49 (2005), 17757–17762.
154. Harisa, G.I., Alanazi, F.K., Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm. J. 22:6 (2014), 504–515.
155. Shaw, M., Lipoproteins as Carriers of Pharmacological Agents. 1991, CRC Press.
156. Glickson, J.D., Lund-Katz, S., Zhou, R., Choi, H., Chen, I.-W., Li, H., et al. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Mol. Imaging, 7(2), 2008, 101.
157. Corbin, I.R., Zheng, G., Mimicking nature's nanocarrier: synthetic low-density lipoprotein-like nanoparticles for cancer-drug delivery. Nanomedicine (Lond.), 2007.
158. Chu, A.C., Tsang, S., Lo, E.H., Fung, K., Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 70:5 (2001), 591–601.
159. Berg, K., Selbo, P., Weyergang, A., Dietze, A., Prasmickaite, L., Bonsted, A., et al. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J. Microsc. 218:2 (2005), 133–147.
160. Chang, J.-E., Yoon, I.-S., Sun, P.-L., Yi, E., Jheon, S., Shim, C.-K., Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer. J. Photochem. Photobiol. B 140 (2014), 49–56.
161. Okamoto, T., Kobayashi, T., Yoshida, S., Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas. Curr. Med. Chem. Anti-Cancer Agents 5:1 (2005), 47–51.
162. Zhang, C.-g., Zhu, Q.-l., Zhou, Y., Liu, Y., Chen, W.-l., Yuan, Z.-Q., et al. N-Succinyl-chitosan nanoparticles coupled with low-density lipoprotein for targeted osthole-loaded delivery to low-density lipoprotein receptor-rich tumors. Int. J. Nanomed., 9, 2014, 2919.
163. Zhu, Q.-l., Zhou, Y., Guan, M., Zhou, X.-f., Liu, Y., Chen, W.-l., et al. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. Biomaterials 35:22 (2014), 5965–5976.
164. Kim, J.-H., Kim, Y., Bae, K.H., Park, T.G., Lee, J.H., Park, K., Tumor-targeted delivery of paclitaxel using low density lipoprotein-Mimetic solid lipid nanoparticles. Mol. Pharm. 12:4 (2015), 1230–1241.
165. Michaelis, K., Hoffmann, M.M., Dreis, S., Herbert, E., Alyautdin, R.N., Michaelis, M., et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317:3 (2006), 1246–1253.
166. Nikanjam, M., Gibbs, A.R., Hunt, C.A., Budinger, T.F., Forte, T.M., Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control. Release 124:3 (2007), 163–171.
167. Liao, J.K., Laufs, U., Pleiotropic effects of statins. Annu. Rev. Pharmacool. Toxicol., 45, 2005, 89.
168. Pinzón‐Daza, M., Garzón, R., Couraud, P., Romero, I., Weksler, B., Ghigo, D., et al. The association of statins plus LDL receptorótargeted liposomeóencapsulated doxorubicin increases in vitro drug delivery across blood?brain barrier cells. Br. J. Pharmacol. 167:7 (2014), 1431–1447.
169. Kreuter, J., Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47:1 (2001), 65–81.
170. Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10:4 (2002), 317–325.
171. Friese, A., Seiller, E., Quack, G., Lorenz, B., Kreuter, J., Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly (butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49:2 (2000), 103–109.
172. Zhang, B., Sun, X., Mei, H., Wang, Y., Liao, Z., Chen, J., et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials 34:36 (2013), 9171–9182.
173. Shrivastava, M., Jain, A., Gulbake, A., Hurkat, P., Jain, N., Vijayraghwan, R., et al. Low density lipid nanoparticles for solid tumor targeting. Sci. Pharm., 82(4), 2014.
174. Reynolds, L., Mulik, R.S., Wen, X., Dilip, A., Corbin, I.R., Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells. Nanomedicine 9:14 (2014), 2123–2141.
175. Zheng, G., Li, H., Zhang, M., Lund-Katz, S., Chance, B., Glickson, J.D., Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjugate Chem. 13:3 (2002), 392–396.
176. Chu, H.-L., Cheng, T.-M., Chen, H.-W., Chou, F.-H., Chang, Y.-C., Lin, H.-Y., et al. Synthesis of apolipoprotein B lipoparticles to deliver hydrophobic/amphiphilic materials. ACS Appl. Mater. Interfaces 5:15 (2013), 7509–7516.
177. Barczyk, M., Carracedo, S., Gullberg, D., Integrins. Cell Tissue Res. 339:1 (2010), 269–280.
178. Ramage, L., Integrins and extracellular matrix in mechanotransduction. Cell Health Cytoskel. 4 (2012), 1–9.
179. Rathinam, R., Alahari, S.K., Important role of integrins in the cancer biology. Cancer Metastasis Rev. 29:1 (2010), 223–237.
180. Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10:1 (2010), 9–22.
181. Humphries, J.D., Byron, A., Humphries, M.J., Integrin ligands at a glance. J. Cell Sci. 119:19 (2006), 3901–3903.
182. Koivunen, E., Wang, B., Ruoslahti, E., Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Nat. Biotechnol. 13:3 (1995), 265–270.
183. Guan, H., McGuire, M.J., Li, S., Brown, K.C., Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of αvβ6-positive cancers. Bioconjugate Chem. 19:9 (2008), 1813–1821.
184. Wang, F., Chen, L., Zhang, R., Chen, Z., Zhu, L., RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J. Control. Release 196 (2014), 222–233.
185. Ji, S., Xu, J., Zhang, B., Yao, W., Xu, W., Wu, W., et al. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer. Biol. Ther. 13:4 (2012), 206–215.
186. Dubey, P.K., Singodia, D., Verma, R.K., Vyas, S.P., RGD modified albumin nanospheres for tumour vasculature targeting. J. Pharm. Pharmacol. 63:1 (2011), 33–40.
187. Temming, K., Meyer, D.L., Zabinski, R., Dijkers, E.C., Poelstra, K., Molema, G., et al. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjugate Chem. 17:6 (2006), 1385–1394.
188. Xiao, Y., Hong, H., Javadi, A., Engle, J.W., Xu, W., Yang, Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 33:11 (2012), 3071–3082.
189. Miura, Y., Takenaka, T., Toh, K., Wu, S., Nishihara, H., Kano, M.R., et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood?brain tumor barrier. ACS Nano 7:10 (2013), 8583–8592.
190. Zhan, C., Gu, B., Xie, C., Li, J., Liu, Y., Lu, W., Cyclic, R.G.D., conjugated poly (ethylene glycol)-co-poly (lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control. Release 143:1 (2010), 136–142.
191. Yang, X., Hong, H., Grailer, J.J., Rowland, I.J., Javadi, A., Hurley, S.A., et al. cRGD-functionalized, DOX-conjugated, and 64 Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 32:17 (2011), 4151–4160.
192. Ding, H., Yong, K.-T., Roy, I., Hu, R., Wu, F., Zhao, L., et al. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology, 22(16), 2011, 165101.
193. Eldar-Boock, A., Miller, K., Sanchis, J., Lupu, R., Vicent, M.J., Satchi-Fainaro, R., Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 32:15 (2011), 3862–3874.
194. Chen, X., Plasencia, C., Hou, Y., Neamati, N., Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem. 48:4 (2005), 1098–1106.
195. Cao, L., Du, P., Jiang, S.-H., Jin, G.-H., Huang, Q.-L., Hua, Z.-C., Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol. Cancer Ther. 7:4 (2008), 851–861.
196. Bertilaccio, M.T., Grioni, M., Sutherland, B.W., Degl'Innocenti, E., Freschi, M., Jachetti, E., et al. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate 68:10 (2008), 1105–1115.
197. Wang, H., Chen, K., Cai, W., Li, Z., He, L., Kashefi, A., et al. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol. Cancer Ther. 7:5 (2008), 1044–1053.
198. Arosio, D., Manzoni, L., Araldi, E.M., Scolastico, C., Cyclic, R.G.D., Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjugate Chem. 22:4 (2011), 664–672.
199. Gormley, A.J., Malugin, A., Ray, A., Robinson, R., Ghandehari, H., Biological evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment. J. Drug Target. 19:10 (2011), 915–924.
200. Garg, A., Tisdale, A.W., Haidari, E., Kokkoli, E., Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 366:1 (2009), 201–210.
201. Shroff, K., Kokkoli, E., PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells. Langmuir 28:10 (2012), 4729–4736.
202. Pangburn, T.O., Georgiou, K., Bates, F.S., Kokkoli, E., Targeted polymersome delivery of siRNA induces cell death of breast cancer cells dependent upon Orai3 protein expression. Langmuir 28:35 (2012), 12816–12830.
203. Marelli, U.K., Rechenmacher, F., Sobahi, T.R.A., Mas-Moruno, C., Kessler, H., Tumor targeting via integrin ligands. Front. Oncol., 3, 2013.
204. Guthi, J.S., Yang, S.-G., Huang, G., Li, S., Khemtong, C., Kessinger, C.W., et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol. Pharm. 7:1 (2009), 32–40.
205. DiCara, D., Rapisarda, C., Sutcliffe, J.L., Violette, S.M., Weinreb, P.H., Hart, I.R., et al. Structure-function analysis of Arg-Gly-Asp helix motifs in αvβ6 integrin ligands. J. Biol. Chem. 282:13 (2007), 9657–9665.
206. Ragelle, H., Colombo, S., Pourcelle, V., Vanvarenberg, K., Vandermeulen, G., Bouzin, C., et al. Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly (ethylene imine) hybrid nanoparticles: a mechanistic insight. J. Control. Release 211 (2015), 1–9 Aug 10.
207. Schiffelers, R.M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32:19 (2004), e149–e.
208. Wang, D., Fei, B., Halig, L.V., Qin, X., Hu, Z., Xu, H., et al. Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano 8:7 (2014), 6620–6632.
209. Guo, Z., He, B., Jin, H., Zhang, H., Dai, W., Zhang, L., et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin α vβ 3 clustering. Biomaterials 35:23 (2014), 6106–6117.
210. Morlieras, J., Dufort, S., Sancey, L., Truillet, C., Mignot, A., Rossetti, F., et al. Functionalization of small rigid platforms with cyclic RGD peptides for targeting tumors overexpressing α vβ 3-integrins. Bioconjugate Chem. 24:9 (2013), 1584–1597.
211. Bolley, J., Lalatonne, Y., Haddad, O., Letourneur, D., Soussan, M., Pérard-Viret, J., et al. Optimized multimodal nanoplatforms for targeting α vβ 3 integrins. Nanoscale 5:23 (2013), 11478–11489.
212. Morales-Avila, E., Ferro-Flores, G., Ocampo-García, B.E., De León-Rodríguez, L.M., Santos-Cuevas, C.L., García-Becerra, R., et al. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c [RGDfK (C)] for molecular imaging of tumor α (v) β (3) expression. Bioconjugate Chem. 22:5 (2011), 913–922.
213. Zhang, C., Jugold, M., Woenne, E.C., Lammers, T., Morgenstern, B., Mueller, M.M., et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 67:4 (2007), 1555–1562.
214. Melemenidis, S., Jefferson, A., Ruparelia, N., Akhtar, A.M., Xie, J., Allen, D., et al. Molecular magnetic resonance imaging of angiogenesis In vivo using polyvalent cyclic RGD-Iron oxide microparticle conjugates. Theranostics, 5(5), 2015, 515.
215. Vilchis-Juárez, A., Ferro-Flores, G., Santos-Cuevas, C., Morales-Avila, E., Ocampo-García, B., Díaz-Nieto, L., et al. Molecular targeting radiotherapy with cyclo-RGDFK (C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice. J. Biomed. Nanotechnol. 10:3 (2014), 393–404.
216. Varki, A., Selectin ligands. Proc. Natl. Acad. Sci. 91:16 (1994), 7390–7397.
217. Hakomori, S-i., Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res., 52(25), 1989, 270.
218. Muramatsu, T., Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiology 3:4 (1993), 291–296.
219. Liu, F.-T., Rabinovich, G.A., Galectins as modulators of tumour progression. Nat. Rev. Cancer 5:1 (2005), 29–41.
220. Gupta, A., Gupta, R.K., Gupta, G., Targeting cells for drug and gene delivery: emerging applications of mannans and mannan binding lectins. J. Sci. Ind. Res., 68(6), 2009, 465.
221. Seymour, L., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31:5 (1995), 766–770.
222. Smart, J.D., Lectin-mediated drug delivery in the oral cavity. Adv. Drug Deliv. Rev. 56:4 (2004), 481–489.
223. David, A., Carbohydrate-based biomedical copolymers for targeted delivery of anticancer drugs. Isr. J. Chem. 50:2 (2010), 204–219.
224. Lee, R.T., Lee, Y.C., Affinity enhancement by multivalent lectin–carbohydrate interaction. Glycoconj. J. 17:7–9 (2000), 543–551.
225. Cho, K.J., Therapeutic nanoparticles for drug delivery in cancer. Kor. J. Otorhinolaryngol. Head Neck Surg. 50:7 (2007), 562–572.
226. Seymour, L.W., Ferry, D.R., Anderson, D., Hesslewood, S., Julyan, P.J., Poyner, R., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20:6 (2002), 1668–1676.
227. D'Souza, A.A., Jain, P., Galdhar, C., Samad, A., Degani, M.S., Devarajan, P.V., Comparative in silico–in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin gantrez nanoparticles. AAPS J. 15:3 (2013), 696–706.
228. Guhagarkar, S.A., Gaikwad, R.V., Samad, A., Malshe, V.C., Devarajan, P.V., Polyethylene sebacate–doxorubicin nanoparticles for hepatic targeting. Int. J. Pharm. 401:1 (2010), 113–122.
229. Sahu, P.K., Mishra, D.K., Jain, N., Rajoriya, V., Jain, A.K., Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel. Drug Dev. Ind. Pharm. 41:4 (2015), 640–649.
230. Jain, A., Agarwal, A., Majumder, S., Lariya, N., Khaya, A., Agrawal, H., et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J. Control. Release 148:3 (2010), 359–367.
231. Andrade, C.G., Cabral Filho, P.E., Tenório, D.P., Santos, B.S., Beltrão, E.I., Fontes, A., et al. Evaluation of glycophenotype in breast cancer by quantum dot-lectin histochemistry. Int. J. Nanomed., 8, 2013, 4623.
232. Ocampo-García, B.E., Ramírez FdM. Ferro-Flores, G., De León-Rodríguez, L.M., Santos-Cuevas, C.L., Morales-Avila, E., et al. 99 m Tc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. Nucl. Med. Biol. 38:1 (2011), 1–11.
233. Higuchi, Y., Oka, M., Kawakami, S., Hashida, M., Mannosylated semiconductor quantum dots for the labeling of macrophages. J. Control. Release 125:2 (2008), 131–136.
234. Li, J., Ma, F.-K., Dang, Q.-F., Liang, X.-G., Chen, X.-G., Glucose-conjugated chitosan nanoparticles for targeted drug delivery and their specific interaction with tumor cells. Front. Mater. Sci. 8:4 (2014), 363–372.
235. Pereira, P.M., Silva, S., Cavaleiro, J.A., Ribeiro, C.A., Tomé, J.P., Fernandes, R., Galactodendritic phthalocyanine targets carbohydrate-binding proteins enhancing photodynamic therapy. PLoS One, 9(4), 2014, e95529.
236. Kluza, E., Jacobs, I., Hectors, S.J., Mayo, K.H., Griffioen, A.W., Strijkers, G.J., et al. Dual-targeting of α vβ 3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Control. Release 158:2 (2012), 207–214.
237. Ley, K., The role of selectins in inflammation and disease. Trends Mol. Med. 9:6 (2003), 263–268.
238. Banquy, X., Leclair, G., Rabanel, J.-M., Argaw, A., Bouchard, J.-F., Hildgen, P., et al. Selectins ligand decorated drug carriers for activated endothelial cell targeting. Bioconjugate Chem. 19:10 (2008), 2030–2039.
239. Obaid, G., Chambrier, I., Cook, M.J., Russell, D.A., Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles. Photochem. Photobiol. Sci. 14:4 (2015), 737–747.
240. He, X., Liu, F., Liu, L., Duan, T., Zhang, H., Wang, Z., Lectin-conjugated Fe2O3@ Au core@ shell nanoparticles as dual mode contrast agents for in vivo detection of tumor. Mol. Pharm. 11:3 (2014), 738–745.
241. Peer, D., Margalit, R., Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia (New York NY), 6(4), 2004, 343.
242. Shen, H., Shi, S., Zhang, Z., Gong, T., Sun, X., Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics, 5(7), 2015, 755.
243. Maiolino, S., Russo, A., Pagliara, V., Conte, C., Ungaro, F., Russo, G., et al. Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells. J. Nanobiotechnology, 13(1), 2015, 29.
244. Yang, X., Singh, A., Choy, E., Hornicek, F.J., Amiji, M.M., Duan, Z., MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci. Rep., 5, 2015.
245. Hall, C.L., Yang, B., Yang, X., Zhang, S., Turley, M., Samuel, S., et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 82:1 (1995), 19–28.
246. Murthy, S.K., Nanoparticles in modern medicine: state of the art and future challenges. Int. J. Nanomed., 2(2), 2007, 129.
247. Mansoori, G.A., Brandenburg, K.S., Shakeri-Zadeh, A., A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications. Cancers 2:4 (2010), 1911–1928.
248. Bahrami, B., Mohammadnia-Afrouzi, M., Bakhshaei, P., Yazdani, Y., Ghalamfarsa, G., Yousefi, M., et al. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumor Biol. 36:8 (2015), 5727–5742.
249. Ye, W.-l., Du, J.-b., Na, R., Song, Y.-f., Mei, Q.-b., Zhao, M.-g., et al. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA. Nanoparticles, 2014.
250. Prabaharan, M., Grailer, J.J., Steeber, D.A., Gong, S., Thermosensitive micelles based on folate-conjugated poly (N-vinylcaprolactam)-block-Poly (ethylene glycol) for tumor-targeted drug delivery. Macromol. Biosci. 9:8 (2009), 744–753.
251. Gao, Z.-G., Tian, L., Hu, J., Park, I.-S., Bae, Y.H., Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J. Control. Release 152:1 (2011), 84–89.
252. Syu, W.J., Yu, H.P., Hsu, C.Y., Rajan, Y.C., Hsu, Y.H., Chang, Y.C., et al. Improved photodynamic cancer treatment by folate-conjugated polymeric micelles in a KB xenografted animal model. Small 8:13 (2012), 2060–2069.
253. Zhang, N., Xia, Y., Guo, X., Wang, P., Yan, S., Lu, C., et al. Preparation, characterization, and in vitro targeted delivery of folate-conjugated 2-methoxyestradiol-loaded bovine serum albumin nanoparticles. J. Nanopart. Res. 16:5 (2014), 1–13.
254. Zhao, D., Zhao, X., Zu, Y., Li, J., Zhang, Y., Jiang, R., et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int. J. Nanomed., 5, 2010, 669.
255. Liang, X., Sun, Y., Liu, L., Ma, X., Hu, X., Fan, J., et al. Folate-functionalized nanoparticles for controlled ergosta-4, 6, 8 (14), 22-tetraen-3-one delivery. Int. J. Pharm. 441:1 (2013), 1–8.
256. Su, C., Li, H., Shi, Y., Wang, G., Liu, L., Zhao, L., et al. Carboxymethyl-β-cyclodextrin conjugated nanoparticles facilitate therapy for folate receptor-positive tumor with the mediation of folic acid. Int. J. Pharm. 474:1 (2014), 202–211.
257. Shen, Z., Li, Y., Kohama, K., Oneill, B., Bi, J., Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacol. Res. 63:1 (2011), 51–58.
258. Hao, H., Ma, Q., Huang, C., He, F., Yao, P., Preparation, characterization, and in vivo evaluation of doxorubicin loaded BSA nanoparticles with folic acid modified dextran surface. Int. J. Pharm. 444:1 (2013), 77–84.
259. Zu, Y., Zhang, Y., Zhao, X., Zhang, Q., Liu, Y., Jiang, R., Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folateconjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM). Int. J. Nanomed., 4, 2009, 321.
260. Martínez, A., Muñiz, E., Teijón, C., Iglesias, I., Teijón, J., Blanco, M., Targeting tamoxifen to breast cancer xenograft tumours: preclinical efficacy of folate-attached nanoparticles based on alginate-cysteine/disulphide-bond-reduced albumin. Pharm. Res. 31:5 (2014), 1264–1274.
261. Yang, R., An, Y., Miao, F., Li, M., Liu, P., Tang, Q., Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo. Int. J. Nanomed., 9, 2014, 4231.
262. Shakeri-Zadeh, A., Mansoori, G.A., Hashemian, A.R., Eshghi, H., Sazgarnia, A., Montazerabadi, A.R., Cancerous cells targeting and destruction using folate conjugated gold nanoparticles. Dyn. Biochem. Process Biotechnol. Mol. Biol. 4:1 (2010), 06–12.
263. Lin, J., Zhou, Z., Li, Z., Zhang, C., Wang, X., Wang, K., et al. Biomimetic one-pot synthesis of gold nanoclusters/nanoparticles for targeted tumor cellular dual-modality imaging. Nanoscale Res. Lett. 8:1 (2013), 1–7.
264. Cheng, J., Gu, Y.-J., Cheng, S.H., Wong, W.T., Surface functionalized gold nanoparticles for drug delivery. J. Biomed. Nanotechnol. 9:8 (2013), 1362–1369.
265. Pandey, S., Mewada, A., Thakur, M., Shah, R., Oza, G., Sharon, M., Biogenic gold nanoparticles as fotillas to fire berberine hydrochloride using folic acid as molecular road map. Mater. Sci. Eng.: C 33:7 (2013), 3716–3722.
266. Prabaharan, M., Grailer, J.J., Pilla, S., Steeber, D.A., Gong, S., Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials 30:30 (2009), 6065–6075.
267. Lu, W., Zhang, G., Zhang, R., Flores, L.G., Huang, Q., Gelovani, J.G., et al. Tumor site?specific silencing of NF-κB p65 by targeted hollow gold nanosphere?mediated photothermal transfection. Cancer Res. 70:8 (2010), 3177–3188.
268. Mehdizadeh, A., Pandesh, S., Shakeri-Zadeh, A., Kamrava, S.K., Habib-Agahi, M., Farhadi, M., et al. The effects of folate-conjugated gold nanorods in combination with plasmonic photothermal therapy on mouth epidermal carcinoma cells. Lasers Med. Sci. 29:3 (2014), 939–948.
269. Majd, M.H., Barar, J., Asgari, D., Valizadeh, H., Rashidi, M.R., Kafil, V., et al. Targeted fluoromagnetic nanoparticles for imaging of breast cancer mcf-7 cells. Adv. Pharm. Bull., 3(1), 2013, 189.
270. Varshosaz, J., Sadeghi-Aliabadi, H., Ghasemi, S., Behdadfar, B., Use of magnetic folate-dextran-retinoic acid micelles for dual targeting of doxorubicin in breast cancer. BioMed Res. Int., 2013, 2013.
271. Fazilati, M., Folate decorated magnetite nanoparticles: synthesis and targeted therapy against ovarian cancer. Cell Biol. Int. 38:2 (2014), 154–163.
272. Wang, H., Wang, S., Liao, Z., Zhao, P., Su, W., Niu, R., et al. Folate-targeting magnetic core–shell nanocarriers for selective drug release and imaging. Int. J. Pharm. 430:1 (2012), 342–349.
273. Carpenter, G., Cohen, S., Epidermal growth factor. Annu. Rev. Biochem 48:1 (1979), 193–216.
274. Wieduwilt, M., Moasser, M., The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 65:10 (2008), 1566–1584.
275. Thompson, D., Gill, G., The, E.G.F., receptor: structure, regulation and potential role in malignancy. Cancer Surv. 4:4 (1984), 767–788.
276. Acharya, S., Dilnawaz, F., Sahoo, S.K., Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30:29 (2009), 5737–5750.
277. Scaltriti, M., Baselga, J., The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12:18 (2006), 5268–5272.
278. Nicholson, R.I., Gee, J.M.W., Harper, M.E., EGFR and cancer prognosis. Eur. J. Cancer 37 (2001), 9–15.
279. Ursini-Siegel, J., Schade, B., Cardiff, R.D., Muller, W.J., Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 7:5 (2007), 389–397.
280. Lurje, G., Lenz, H.-J., EGFR signaling and drug discovery. Oncology 77 (2009), 400–410.
281. Mendelsohn, J., The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8:1 (2001), 3–9.
282. Gridelli, C., Maione, P., Bareschino, M.A., Schettino, C., Sacco, P.C., Ambrosio, R., et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res. 30:4 (2010), 1301–1310.
283. Tseng, C.-L., Wu, S.Y.-H., Wang, W.-H., Peng, C.-L., Lin, F.-H., Lin, C.-C., et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 29:20 (2008), 3014–3022.
284. Tseng, C.-L., Wang, T.-W., Dong, G.-C., Wu, S.Y.-H., Young, T.-H., Shieh, M.-J., et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28:27 (2007), 3996–4005.
285. Shimada, T., Ueda, M., Jinno, H., Chiba, N., Wada, M., Watanabe, J., et al. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res. 29:4 (2009), 1009–1014.
286. Tam, N.C., Scott, B.M., Wilson, B.C., Zheng, G., Lung Cancer Targeted Raman Active Phospholipid Gold Nanoparticles for Ultrasensitive and Specific Molecular Imaging and Detection. European Conferences on Biomedical Optics. 2011, International Society for Optics and Photonics.
287. Yuan, Q., Lee, E., Yeudall, W.A., Yang, H., Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. Oral Oncol. 46:9 (2010), 698–704.
288. Li, J., Chen, L., Liu, N., Li, S., Hao, Y., Zhang, X., EGF-coated nano-dendriplexes for tumor-targeted nucleic acid delivery in vivo. Drug Deliv. 2015:0 (2015), 1–8.
289. Sandoval, M.A., Sloat, B.R., Lansakara-P, D.S., Kumar, A., Rodriguez, B.L., Kiguchi, K., et al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J. Control. Release 157:2 (2012), 287–296.
290. Nikolaev, B.P., Marchenko, Y.Y., Yakovleva, L.Y., Zimina, T.M., Soloviev, A.V., Luchinin, V.V., et al. Magnetic epidermal growth factor conjugate for targeted delivery to grafted tumor in mouse model. IEEE Trans. Magnet. 49:1 (2013), 429–435.
291. Shevtsov, M.A., Nikolaev, B.P., Yakovleva, L.Y., Marchenko, Y.Y., Dobrodumov, A.V., Mikhrina, A.L., et al. Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION–EGF) for targeting brain tumors. Int. J. Nanomed., 9, 2014, 273.
292. Han, C.-y., Yue, L.-l., Tai, L.-l., Zhou, L., Li, X.-y., Xing, G.-h., et al. A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro. Int. J. Nanomed., 8, 2013, 1541.
293. Kim, S.K., Huang, L., Nanoparticle delivery of a peptide targeting EGFR signaling. J. Control. Release 157:2 (2012), 279–286.
294. Xu, J., Amiji, M., Therapeutic gene delivery and transfection in human pancreatic cancer cells using epidermal growth factor receptor-targeted gelatin nanoparticles. J. Visual. Exp.: JoVE(59), 2012.
295. Song, S., Liu, D., Peng, J., Deng, H., Guo, Y., Xu, L.X., et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J. 23:5 (2009), 1396–1404.
296. Chen G-CL, T-S. Jaw, Y-T. Kuo, C-Y. Chen, Y-M. Wang, Targeted new peptide based nanoparticles toward high EGFR expressing cancer cells for MRI 2010.
297. Klutz, K., Schaffert, D., Willhauck, M.J., Grünwald, G.K., Haase, R., Wunderlich, N., et al. Epidermal growth factor receptor-targeted 131I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol. Ther. 19:4 (2011), 676–685.
298. Ren, H., Gao, C., Zhou, L., Liu, M., Xie, C., Lu, W., EGFR-targeted poly (ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation. Drug Deliv.(0), 2014, 1–10.
299. Master, A.M., Qi, Y., Oleinick, N.L., Gupta, A.S., EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomed.: Nanotechnol. Biol. Med. 8:5 (2012), 655–664.
300. Chariou, P.L., Lee, K.L., Wen, A.M., Gulati, N.M., Stewart, P.L., Steinmetz, N.F., Detection and imaging of aggressive cancer cells using an epidermal growth factor receptor (EGFR)-targeted filamentous plant virus-based nanoparticle. Bioconjugate Chem. 26:2 (2015), 262–269.
301. Magadala, P., Amiji, M., Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 10:4 (2008), 565–576.
302. Keefe, A.D., Pai, S., Ellington, A., Aptamers as therapeutics. Nat. Rev. Drug Discov. 9:7 (2010), 537–550.
303. Li, N., Larson, T., Nguyen, H.H., Sokolov, K.V., Ellington, A.D., Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. 46:3 (2010), 392–394.
304. Kazemi, T., Younesi, V., Jadidi-Niaragh, F., Yousefi, M., Immunotherapeutic approaches for cancer therapy: an updated review. Artif. Cells Nanomed. Biotechnol. 44:3 (2016), 769–779.
305. Jadidi-Niaragh, F., Atyabi, F., Rastegari, A., Mollarazi, E., Kiani, M., Razavi, A., et al. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Tumor Biol. 37:6 (2016), 8403–8412.
306. Frasco, M.F., Almeida, G.M., Santos-Silva, F., Pereira, M.d.C., Coelho, M.A., Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells. J. Biomed. Mater. Res. A, 2014.
307. Wang, Q., Li, J., An, S., Chen, Y., Jiang, C., Wang, X., Magnetic resonance-guided regional gene delivery strategy using a tumor stroma-permeable nanocarrier for pancreatic cancer. Int. J. Nanomed., 10, 2015, 4479.
308. Xia, H., Gu, G., Hu, Q., Liu, Z., Jiang, M., Kang, T., et al. Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug. Bioconjugate Chem. 24:3 (2013), 419–430.
309. Yang, Y., Jiang, Y., Wang, Z., Liu, J., Yan, L., Ye, J., et al. Skin-permeable quaternary nanoparticles with layer-by-layer structure enabling improved gene delivery. J. Mater. Chem. 22:19 (2012), 10029–10034.
310. Tseng, Y.-L., Liu, J.-J., Hong, R.-L., Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol. Pharmacol. 62:4 (2002), 864–872.
311. Xia, H., Gao, X., Gu, G., Liu, Z., Hu, Q., Tu, Y., et al. Penetratin-functionalized PEG?PLA nanoparticles for brain drug delivery. Int. J. Pharm. 436:1 (2012), 840–850.
312. Goldammer, T., The Effect of Penetratin and Silica Capping Agents on Silver Nanoparticle Cellular Uptake in a Caco-2 Cellline. 2013.
313. El-Andaloussi, S., Johansson, H., Magnusdottir, A., Järver, P., Lundberg, P., Langel, Ü., TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. J. Control. Release 110:1 (2005), 189–201.
314. Lehto, T., Simonson, O.E., Mäger, I., Ezzat, K., Sork, H., Copolovici, D.-M., et al. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol. Ther. 19:8 (2011), 1457–1467.
315. MacKay, J.A., Chen, M., McDaniel, J.R., Liu, W., Simnick, A.J., Chilkoti, A., Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater. 8:12 (2009), 993–999.
316. McDaniel, J.R., MacEwan, S.R., Dewhirst, M., Chilkoti, A., Doxorubicin-conjugated chimeric polypeptide nanoparticles that respond to mild hyperthermia. J. Control. Release 159:3 (2012), 362–367.
317. Myrberg, H., Zhang, L., Mäe, M., Langel, Ü., Design of a tumor-homing cell-penetrating peptide. Bioconjugate Chem. 19:1 (2007), 70–75.
318. Oehlke, J., Wallukat, G., Wolf, Y., Ehrlich, A., Wiesner, B., Berger, H., et al. Enhancement of intracellular concentration and biological activity of PNA after conjugation with a cell-penetrating synthetic model peptide. Eur. J. Biochem. 271:14 (2004), 3043–3049.
319. Gao, H., Zhang, Q., Yang, Y., Jiang, X., He, Q., Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy. Int. J. Pharm. 478:1 (2015), 240–250.
320. Lewin, M., Carlesso, N., Tung, C.-H., Tang, X.-W., Cory, D., Scadden, D.T., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18:4 (2000), 410–414.
321. Dodd, C.H., Hsu, H.-C., Chu, W.-J., Yang, P., Zhang, H.-G., Mountz, J.D., et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J. Immunol. Methods 256:1 (2001), 89–105.
322. Goswami, D., Vitorino, H.A., Machini, M.T., Espósito, B.P., Self-assembled penetratin-deferasirox micelles as potential carriers for hydrophobic drug delivery. Pept. Sci. 104:6 (2015), 712–719 Nov.
323. Tiwari, P.M., Eroglu, E., Bawage, S.S., Vig, K., Miller, M.E., Pillai, S., et al. Enhanced intracellular translocation and biodistribution of gold nanoparticles functionalized with a cell-penetrating peptide (VG-21) from vesicular stomatitis virus. Biomaterials 35:35 (2014), 9484–9494.
324. Suk, J.S., Suh, J., Choy, K., Lai, S.K., Fu, J., Hanes, J., Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles. Biomaterials 27:29 (2006), 5143–5150.
325. Juliano, R., Intracellular delivery of oligonucleotide conjugates and dendrimer complexes. Ann. N. Y. Acad. Sci. 1082:1 (2006), 18–26.
326. Reynolds, J.L., Law, W.C., Mahajan, S.D., Aalinkeel, R., Nair, B., Sykes, D.E., et al. Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages. J. Neuroimmune Pharmacol. 7:3 (2012), 673–685.
327. Hami, Z., Amini, M., Ghazi-Khansari, M., Rezayat, S.M., Gilani, K., Doxorubicin-conjugated PLA-PEG-Folate based polymeric micelle for tumor-targeted delivery: synthesis and in vitro evaluation. DARU J. Pharm. Sci., 22(1), 2014, 30.
328. Wu, W.-C., Huang, C.-M., Liao, P.-W., Dual-sensitive and folate-conjugated mixed polymeric micelles for controlled and targeted drug delivery. React. Funct. Polym. 81 (2014), 82–90.
329. Guo, X., Shi, C., Wang, J., Di, S., Zhou, S., pH-triggered intracellular release from actively targeting polymer micelles. Biomaterials 34:18 (2013), 4544–4554.
330. Kim, D., Lee, E.S., Oh, K.T., Gao, Z.G., Bae, Y.H., Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 4:11 (2008), 2043–2050.